treatment

Biotech sticks it to stocks – CNBC.com

“That’s a high-profile move. That could make people concerned,” said Steve Massocca of Wedbush Securities. “It’s not exactly the cheapest group around. It’s got an elevated valuation here. It does nothing but go up. It doesn’t take much to create a wobble.””It doesn’t appear to be hurting other speculative areas. The social media index is up three-quarters of a percent,” […]